3Billion Inc is a Korea-based company principally engaged in the provision of genetic testing services. The Company is principally engaged in the provision of rare genetic disease diagnostic testing services. The Company is also engaged in the research and development of technology that automatically reads the pathogenicity of numerous genetic variants found in the genome.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26/06/26	₩5,640.00	-5.21%	248,520
25/06/26	₩5,950.00	-6.89%	129,659
24/06/26	₩6,390.00	+6.32%	615,326
23/06/26	₩6,010.00	-7.25%	170,281
22/06/26	₩6,480.00	-3.57%	113,327

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 26/06/2026			5-day change	1st Jan Change
5,640.00 ^KRW	-5.21%		-16.07%	-69.06%

06-01	3billion Launches 3B-NEO, Genomic Newborn Screening Service Covering 595 Clinically Actionable Genetic Conditions	CI
05-12	3billion, Inc. announced that it has received KRW 29.999999888 billion in funding from Meritz Securities Co., Ltd., Wonik Investment Partners Co., Ltd.	CI

Market Cap	179B 117M 103M 94.58M 88.55M 166M 11.04B 169M 1.14B 440M 5.46B 439M 430M 18.92B	P/E 2025	-107x	P/E 2026 *	-148x
Enterprise Value	163M 106K 92.95K 85.68K 80.21K 150K 10M 154K 1.03M 398K 4.94M 398K 389K 17.14M	EV / Sales 2025	49x	EV / Sales 2026 *	8.72x
Free-Float	75.48%	Yield 2025 *	-	Yield 2026 *	-

06-01	3billion Launches 3B-NEO, Genomic Newborn Screening Service Covering 595 Clinically Actionable Genetic Conditions	CI
05-12	3billion, Inc. announced that it has received KRW 29.999999888 billion in funding from Meritz Securities Co., Ltd., Wonik Investment Partners Co., Ltd.	CI
04-22	3billion, Inc. announced that it expects to receive KRW 29.999999888 billion in funding from Meritz Securities Co., Ltd., Wonik Investment Partners Co., Ltd. and other investors.	CI
04-09	3Billion Inc wins 955 million won order	RE
03-23	3billion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
18/03/25	3Billion Inc Wins 655 Million Won Order	RE

1 day	-5.21%
1 week	-16.07%
Current month	-36.13%
1 month	-39.29%
3 months	-58.13%
6 months	-68.47%
Current year	-69.06%

3billion, Inc. Share Price

Stocks

A394800

KR7394800007

Biotechnology & Medical Research

Valuation: 3billion, Inc.

Chart: 3billion, Inc.

Latest news : 3billion, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: 3billion, Inc.

Latest insider transactions

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	5,600	6,490
1 month	5,600	9,240
Current year	5,600	18,690
1 year	5,520	20,100
3 years	3,025	20,100
5 years	3,025	20,100
10 years	3,025	20,100

Manager	Title	Age	Since
Chang-Won Geum CEO	Chief Executive Officer	45	09/10/2016
Soon-Il Park DFI	Director of Finance/CFO	46	30/09/2020
Jeong-Seol Lee CTO	Chief Tech/Sci/R&D Officer	46	31/07/2018

Director	Title	Age	Since
Chang-Won Geum BRD	Director/Board Member	45	09/10/2016
Se-Hwan Kim BRD	Director/Board Member	44	09/10/2016
Ki-Hyeon Kang BRD	Director/Board Member	44	17/11/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/04/25	Soon-Il Park	Others	Chief Financial Officer	44,000	0.1387%
06/03/25	Ki-hyun Kang	Fiscal year		10,000	0.0316%
06/03/25	Ki-hyun Kang	Others		220,600	0.6963%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
3BILLION, INC.	-5.21%	-16.07%	-21.34%	-	117M
VERACYTE, INC.	+3.31%	+12.79%	+120.93%	+133.91%	4.83B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+3.51%	+19.57%	+77.78%	+205.54%	3.35B
BGI GENOMICS CO., LTD.	-4.54%	-2.42%	-29.51%	-42.93%	1.96B
IOVANCE BIOTHERAPEUTICS, INC.	+0.95%	+8.70%	+151.48%	-42.41%	1.9B
CAREDX, INC.	+3.48%	+10.08%	+49.87%	+228.62%	1.49B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+1.63%	+19.62%	+151.82%	-50.08%	917M
SEEGENE, INC.	-3.95%	+0.72%	-15.15%	+34.94%	842M
HANGZHOU ALLTEST BIOTECH CO., LTD.	-1.09%	-7.70%	-38.35%	-20.12%	466M
CURIOX BIOSYSTEMS CO., LTD	-8.07%	-26.89%	-0.51%	-	435M
Average	-1.00%	+2.83%	+44.70%	+55.93%	1.63B
Weighted average by Cap.	+1.19%	+9.55%	+76.96%	+94.35%

	2025	2026 *
Net sales	10.8B 7.04M 6.17M 5.69M 5.33M 9.99M 664M 10.2M 68.41M 26.47M 328M 26.44M 25.87M 1.14B	18.7B 12.19M 10.69M 9.85M 9.23M 17.3M 1.15B 17.66M 118M 45.83M 568M 45.79M 44.79M 1.97B
Net income	-5.8B -3.78M -3.32M -3.06M -2.86M -5.37M -357M -5.48M -36.74M -14.22M -176M -14.2M -13.89M -611M	-1.2B -782K -686K -632K -592K -1.11M -73.81M -1.13M -7.6M -2.94M -36.48M -2.94M -2.87M -126M
Net Debt	-16.9B -11.02M -9.66M -8.91M -8.34M -15.64M -1.04B -15.96M -107M -41.42M -514M -41.38M -40.48M -1.78B	-16.4B -10.69M -9.38M -8.64M -8.09M -15.17M -1.01B -15.49M -104M -40.2M -499M -40.15M -39.28M -1.73B